{"id":"9918cb0d3999","type":"article","url":"https://hartvaat.nl/2019/07/01/qt-als-voorspeller-van-af-recidief-na-ablatie-en-amiodaronimpact-amio-cat/","title":"QT als voorspeller van AF-recidief na ablatie en amiodaronimpact: AMIO-CAT","title_en":"QT as a predictor of recurrence after atrial fibrillation ablation and the impact of amiodarone: results from the placebo-controlled AMIO-CAT trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euz028","source_url":"https://doi.org/10.1093/europace/euz028","authors":["Søren Zöga Diederichsen","Stine Darkner","Xu Chen","Arne Johannessen","Steen Pehrson","Jim Hansen","Jesper Hastrup Svendsen"],"significance":5,"published":"2019-07-01","source_date":"2019-07-01","image":"","kennis":[],"congress":"","summary_en":"This AMIO-CAT analysis evaluated QT interval as a predictor of AF recurrence after ablation and the impact of short-term amiodarone therapy, testing whether ECG markers can identify patients at risk for post-ablation arrhythmia.","created":"2026-07-03T10:28:01Z","updated":"2026-07-03T13:27:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Analyse van de AMIO-CAT-trial naar QT-interval als voorspeller van AF-recidief na ablatie en het effect van amiodaron.","abstract_original":"AIMS: Prolonged corrected QT interval (QTc) might be associated with arrhythmia recurrence after atrial fibrillation (AF) ablation. The effect of short-term amiodarone in this setting remains unknown. This study seeks to quantify short-term amiodarone's impact on QTc, and to investigate QTc and amiodarone treatment as predictors of recurrence of arrhythmia after ablation. METHODS AND RESULTS: The Short-term AMIOdarone treatment after CATheter ablation for atrial fibrillation (AMIO-CAT) trial randomized patients to 8 weeks of oral amiodarone or placebo following AF ablation. Scheduled and symptom-driven 12-lead electrocardiography and 3-day Holter-monitorings were performed. The endpoint was atrial fibrillation, atrial flutter or atrial tachycardia (AF/AT) lasting >30 s. The cut-off for prolonged QTc was 450 ms for men and 460 ms for women. A total of 212 patients were included, of which 108 were randomized to amiodarone and 104 to placebo. From baseline to 1 month QTc in the amiodarone group increased by 27 (±30) ms, while at 6 months QTc had normalized. After 3-months of blanking, new AF/AT recurrence was detected in 63% of patients with prolonged QTc vs. 41% of patients with normal QTc at baseline, and in multivariate Cox regression, prolonged QTc was associated with AF/AT recurrence [hazard ratio (HR) 2.19, P = 0.023]. Among patients with baseline QTc below median, amiodarone treatment decreased the rate of AF/AT recurrences (HR 0.43, P = 0.008). CONCLUSIONS: Amiodarone increased QTc with 27 ms compared to placebo, and this effect decreased rapidly after drug discontinuation. Prolonged QTc at baseline independently predicted AF/AT recurrence, and baseline QTc identified patients who would possibly benefit from short-term amiodarone following ablation."}